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Posttraumatic stress disorder (PTSD) is an anxiety disorder that may
develop following exposure to a traumatic event. The diagnosis of PTSD
has undergone a number of changes since initial inclusion in the
Diagnostic and Statistical Manual of Mental Disorders (DSM-III)
(American Psychiatric Association, 2015). Some of the changes center
on the definition of what constitutes a traumatic event. In DSM-III,
PTSDwas diagnosed following a “catastrophic stressor that was outside
the range of usual human experience.” However, given the prevalence
of many types of trauma, distinguishing between ordinary and extraor-
dinary events can be challenging. With DSM-IV, the focus turned to the
individual's peri-traumatic reaction of experiencing intense fear, help-
lessness or horror to define the stressor as traumatic. (American Psychi-
atric Association, 2000). However, many individuals fail to endorse this
reaction at the time of the event. The most recent iteration of PTSD in
the DSM-5 removes this criteria and instead identifies the types of
events capable of producing PTSD (e.g., combat, death, threatened
death, serious injury, sexual violence), which are either directly experi-
enced, witnessed, experienced by a close family member or friend, or
experienced through repeated or extreme exposure to aversive details
of the traumatic event. The DSM-5 categorizes PTSD symptoms as: re-
experiencing, avoidance, negative alterations in mood and cognition,
and alterations in arousal and reactivity. (American Psychiatric
Association, 2015). The addition of “persistent and exaggerated nega-
tive beliefs about oneself, others or the world;” and “persistent,
distorted cognitions about the cause or consequences of the event(s)”
are new in DSM-5 and reflect contemporary cognitive-behavioral theo-
ry and research on the after-effects of trauma (Cox, Resnick, &
Kilpatrick, 2014).
PTSD develops in up to a third of individuals who are exposed to
extreme stressors, and symptoms almost always emerge within days
of the exposure (Committee on Treatment of Posttraumatic Stress
Disorder, & Institute of Medicine, 2008). Shortly after exposure, many
people experience some symptoms of PTSD. In most people, those
symptoms resolve within several weeks. However, in approximately
10 to 20%, PTSD symptoms persist and are associated with impairmentPlease cite this article as: Cusack, K., et al., Psychological treatments for adu
analysis, Clinical Psychology Review (2015), http://dx.doi.org/10.1016/j.cprin functioning (Norris & Sloane, 2007). Although approximately 50% of
those diagnosed with PTSD improve without treatment in 1 year, 10
to 20% develop a chronic unremitting course (Fletcher, Creamer, &
Forbes, 2010). In 2000, the estimated lifetime prevalence of PTSD
among adults in the United States was 6.8% and current (12-month)
prevalence was 3.6% (Dohrenwend et al., 2006).
Many people with PTSD never receive treatment. For example, less
than half of individuals who screened positive for PTSD after serving
with the US military in Iraq or Afghanistan were referred for further
evaluation or treatment, and of these, only 65% received care
(Committee on the Assessment of Ongoing Effects in the Treatment of
Posttraumatic Stress Disorder, I. o. M., 2012). Some possible reasons
for never receiving treatment include stigma, access barriers, and uncer-
tainty about which treatments are available and effective (Kuehn,
2012).
Treatments available for PTSD span a variety of psychological and
pharmacological categories.
Among the psychological therapies are trauma-focused psychologi-
cal interventions that treat PTSD by directly addressing thoughts, feel-
ings, or memories of the traumatic event (e.g., exposure therapy,
cognitive therapy); and non-trauma-focused psychological interven-
tions, which aim to help the individual's experience of PTSD
symptoms but do not directly target thoughts and feelings related to
the trauma (e.g., relaxation, Stress Inoculation Training, and interper-
sonal therapy).
Numerous organizations have produced guidelines for the treat-
ment of patients with PTSD, including the American Psychiatric Associ-
ation (APA), the U.S. Department of Veterans Affairs (VA)/Department
of Defense (DoD), the United Kingdom's National Institute for Health
and Clinical Excellence (NICE), ISTSS, the Institute of Medicine (IOM),
the American Academy of Child and Adolescent Psychiatry (AACAP),
and the Australian National Health and Medical Research Council
(NHMRC). Table 1 summarizes the previous guidelines. In addition to
employing a wide range of methodologies, the various guidelines differ
in the level of rigor of studies included in their review. For instance,
some were based on expert review of the literature (VA/DoD, APA,
and ISTSS). Other guidelines were based on meta-analysis of RCTs butlts with posttraumatic stress disorder: A systematic review andmeta-
.2015.10.003
Table 1
Clinical Practice Guidelines for PTSD.
Clinical Practice Guideline Methodology Criteria for level I rating Level I
therapies
Criteria for Level II rating Level II
therapies
VA/DoD Clinical Practice Guideline
Working Group (2004)
Expert review; RCTs, lower
levels if no RCT available
At least 1 well-conducted
RCT demonstrating efficacy
CT, Exp, SIT,
EMDR
Well-designed controlled trial
without randomization
IRT,
Psychodynamic
therapy
American Psychiatric Association (2004) Expert review; RCTs, lower
levels if no RCT available
Randomized, double-blinded
clinical trial
TF-CBT RCT not double-blinded EMDR, SIT, IRT
National Institute for Health and Clinical
Excellence (2005)
Meta-analysis; RCTs Medium effect size or better
from at least 1 RCT
TF-CBT, EMDR Evidence from at least 1
well-designed study (non-RCT)
N/A
Australian National Health and Medical
Research Council (NHMRC) Guidelines,
and Australian Centre for Posttraumatic
Mental Health (2007)
Meta-analysis; RCTs Medium effect size or better
from at least 1 RCT
TF-CBT, EMDR
with in vivo
Evidence from at least 1
well-designed study (non-RCT)
Stress
Management
ISTSS (Foa et al., 2008) Expert review; All levels of
studies
Well controlled RCTs Exp, CPT, CT,
SIT, EMDR
Well-designed clinical studies w/o
randomization or control condition
Psychodynamic
therapy
Institute of Medicine (2007) Independent review;
rigorous criteria for RCTs
More than 1 study indicating
clinically meaningful effect;
high confidence in presence
and magnitude of effect
Exp (includes
CPT studies)
Controlled trial w/o randomization N/A
CT = Cognitive therapy; EXP = exposure therapy; SIT = stress inoculation therapy; EMDR = eye movement desensitization and reprocessing; TF-CBT = trauma focused CBT; CPT =
cognitive processing therapy; IRT = imagery rehearsal therapy; RCT = randomized control trial.
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the IOM report had strict inclusion criteria based on randomized con-
trolled trials, adequate sample sizes, minimal level of dropout, blinding
of assessors, and adequatemethods used to handlemissing data. Each of
the guidelines identified therapies that warranted a highest level of rec-
ommendation (Level I), followed by a second-level recommendation
(Level II). The guidelines used different criteria for determining what
merited a Level I recommendation, ranging from having at least one
RCT (e.g., VA/DoD) to having at least one RCT meeting all of the strict
criteria as outlined above (e.g., IOM). All of the existing guidelines
agree that trauma-focused psychological interventions including expo-
sure therapy and cognitive therapy are effective, empirically supported
first-line treatments for PTSD. (American Psychiatric Association, 2004;
Foa, Keane, Friedman, & Cohen, 2008; Forbes et al., 2010; National Insti-
tute for Health and Clinical Excellence, 2005; VA/DoD Clinical Practice
Guideline Working Group, 2004). In addition, four of the six guidelines
(VA/DoD, NICE, NHMRC, and ISTSS) agree that EMDR is a first-line treat-
ment for PTSD, and two of the guidelines agree that Stress Inoculation
Therapy is a first-line treatment for PTSD. The IOM report concluded
that only exposure therapy was efficacious and recommended as a
first line treatment (Committee on Treatment of Posttraumatic Stress
Disorder, & Institute of Medicine, 2008).
Most guidelines identify trauma-focused psychological treatments
over pharmacological treatments as a preferredfirst step and viewmed-
ications as an adjunct or a next line treatment (American Psychiatric As-
sociation, 2004; Australian National Health and Medical Research
Council (NHMRC) Guidelines, & Australian Centre for Posttraumatic
Mental Health, 2007; National Institute for Health and Clinical
Excellence, 2005; VA/DoD Clinical Practice Guideline Working Group,
2004. Most recognize at least some benefit of pharmacologic treatment
for PTSD, with the exception of one from the IOM. The IOM report found
insufficient evidence to recommend any medication owing to poor
study design or inconsistent results. Some guidelines acknowledge
that practical considerations, such as unavailability of trauma-focused
psychological treatment or patient preferences, may guide treatment
decisions (Foa et al., 2008).
As a result of differences in methodologies and categorization of
therapies, the available guidelines leave important questions unan-
swered. One important question is the relative magnitude of effect for
exposure therapy and cognitive therapies separately, as previous
reviews analyzed them together. Another question concerns the degree
to which EMDR is beneficial, as all guidelines except for the more
rigorous IOM report gave EMDR a primary or secondary level of recom-
mendation. Further, these guidelines were developed between 7 andPlease cite this article as: Cusack, K., et al., Psychological treatments for adu
analysis, Clinical Psychology Review (2015), http://dx.doi.org/10.1016/j.cpr11 years ago, and new trials have since been published that can add to
the evidence base. Finally, the current manuscript attempted to address
the potential adverse effects of treatments for PTSD,which had not been
addressed in previous reviews.
In this article, we updated our prior meta-analyses of psychological
treatments for PTSD that were conducted for the Effective Health Care
Program of the Agency for Healthcare Research and Quality (AHRQ)
(Jonas et al., 2013). The prior meta-analyses were part of a larger
technical report on the efficacy, comparative effectiveness, and adverse
effects of psychological and pharmacological treatments for adults with
PTSD.
2. Methods
Wedeveloped and followed a standard protocol. Our previous techni-
cal report that further details methods and includes search strategies and
additional evidence tables is available at: http://effectivehealthcare.ahrq.
gov/ehc/products/347/1435/PTSD-adult-treatment-report-130403.pdf.
The technical report addressed six questions (Table S1) (Jonas et al.,
2013).
2.1. Data sources and searches
We searched MEDLINE, the Cochrane Library, the PILOTS database,
CINAHL, PsycINFO, EMBASE,Web of Science, and International Pharma-
ceutical Abstracts for English-language articles from January 1, 1980, to
May 24, 2012, for the technical report. The current article was updated
to include studies published through May 20, 2014. The start date was
selected based on the introduction of PTSD as a clinical entity, previous
reviews, and expert opinion. We used Medical Subject Headings as
search termswhen available and keywordswhen appropriate, focusing
on terms to describe relevant populations and treatments.Wemanually
searched reference lists of reviews and included trials to look for cita-
tions that our searches missed. We searched for unpublished studies
using ClinicalTrials.gov, theWeb site for the Food and Drug Administra-
tion, and the World Health Organization's International Clinical Trials
Registry Platform.
2.2. Study selection
Wedeveloped inclusion and exclusion criteria with respect to popu-
lations, interventions, comparators, outcomes, timing, settings, and
study designs. We included randomized controlled trials of at least
4 weeks in duration enrolling adults with PTSD based on DSM criterialts with posttraumatic stress disorder: A systematic review andmeta-
.2015.10.003
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tion compared with waitlist, usual care, no intervention, placebo, or an-
other psychological or pharmacological intervention.We included trials
where the follow-up period was at least 4 weeks post-treatment in
order to capture change in PTSD symptoms.
The following psychological treatments were eligible: brief eclectic
psychotherapy; cognitive behavioral therapies (CBT) such as cognitive
therapy (CT), including cognitive processing therapy (CPT), cognitive
restructuring (CR), coping skills therapy (including stress inoculation
therapy), and exposure therapy, including prolonged exposure; eye
movement desensitization and reprocessing (EMDR); hypnotherapy;
interpersonal therapy; psychodynamic therapy; and narrative exposure
therapy (NET). These therapies are designed to minimize the intrusion,
avoidance, and hyperarousal symptoms of PTSD by some combination
of re-experiencing and working through trauma-related memories
and emotions and teaching better methods of managing trauma-
related stressors (Committee on Treatment of Posttraumatic Stress
Disorder, & Institute of Medicine, 2008).
Brief eclectic psychotherapy is a 16-session manualized treatment
for PTSD that combines cognitive-behavioral and psychodynamic ap-
proaches (Gersons, Carlier, Lamberts, & van der Kolk, 2000; Gersons,
Carlier, & Olff, 2004). It consists of (1) psychoeducation, together with
a partner or close friend; (2) imaginal exposure preceded by relaxation
exercises, focused on catharsis of emotions of grief and helplessness;
(3) writing tasks to express aggressive feelings and the use of memen-
tos; (4) domain of meaning, focused on learning from the trauma; and
(5) a farewell ritual, to end treatment. It was originally developed as a
treatment for police officers, but it has also been usedwith other trauma
samples.
CBT is a broad category of therapies based on principles of learning
and conditioning and/or cognitive theory to treat disorders and includes
components from both behavioral and cognitive therapy. In CBT, com-
ponents such as exposure, cognitive restructuring, and various coping
skills have been used either alone or in combination. Most forms of
CBT consist of a minimum of 8 to 12 weekly sessions lasting 60 to
90 min. CBT can be administered either as group or individual therapy
(Committee on Treatment of Posttraumatic Stress Disorder,, &
Institute of Medicine, 2008; Foa et al., 2008; Friedman, 2003; Harvey,
Bryant, & Tarrier, 2003). It has both specific and nonspecific (i.e., more
general ormixed) types; three specific types are described below.
Cognitive therapy is used to describe interventions that are largely
based on the cognitive model, which states that an individual's percep-
tion of a situation influences his or her emotional response to it. The
general goal of cognitive therapy is to help people identify distorted
thinking and to modify existing beliefs, so that they are better able to
cope and change problematic behaviors. Cognitive therapy is generally
considered to be brief, goal oriented, and time limited. Variants of
cognitive therapy have been developed. Among these are cognitive
restructuring and CPT.
Cognitive processing therapy includes psychoeducation, written
accounts about the traumatic event, and cognitive restructuring
addressing the beliefs about the event's meaning and the implications
of the trauma for one's life (Resick & Schnicke, 1993). The treatment is
based on the idea that negative emotional reactions can interfere with
emotional and cognitive processing of the trauma memory, which can
lead to traumatic symptomatology. Themanualized treatment is gener-
ally delivered over 12 sessions lasting 60 to 90 min (Resick & Schnicke,
1993). (A manualized treatment is based on a guidebook that defines
the specific procedures and tactics used to implement the treatment;
the use of a manual facilitates standardization of a therapy across
settings and therapists.)
Cognitive restructuring is based on the theory that the interpretation
of the event, rather than the event itself, determines an individual's
emotional reactions. It aims to facilitate relearning thoughts and beliefs
generated from a traumatic event, to increase awareness of dysfunc-
tional trauma-related thoughts, and to correct or replace those thoughtsPlease cite this article as: Cusack, K., et al., Psychological treatments for adu
analysis, Clinical Psychology Review (2015), http://dx.doi.org/10.1016/j.cprwith more adaptive and rational cognitions. Cognitive restructuring gen-
erally takes place over 8 to 12 sessions of 60 to 90 min (Committee on
Treatment of Posttraumatic Stress Disorder, & Institute of Medicine,
2008; Foa et al., 2008).
Coping skills therapies may include components such as stress
inoculation training, assertiveness training, biofeedback (including
brainwave neurofeedback), or relaxation training. These therapies
may use techniques such as education, muscle relaxation training,
breathing retraining, role playing, or similar interventions to manage
anxiety or correct misunderstandings that developed at the time of
trauma. The therapy is designed to increase coping skills for current sit-
uations and intentionally does not target trauma-related memories or
cognitions. Most types of coping skills therapies require at least eight
sessions of 60 to 90 min; more comprehensive interventions such as
stress inoculation training require 10 to 14 sessions (Committee on
Treatment of Posttraumatic Stress Disorder, & Institute of Medicine,
2008; Foa et al., 2008). Of note, this category includes a range of active
psychotherapeutic treatments (e.g., stress inoculation training) and
some comparison treatments that are generally intended as a control
group (e.g., relaxation). Consequently, in this report we do not attempt
to determine any overall effect for this category (as onewould not have
sufficient clinical relevance); rather we determine results separately for
the various therapies we have included in this category. In addition, not
all of these coping skills are CBT—for example, a CBT protocol might
include relaxation training, but relaxation is not exclusively CBT.
Exposure-based therapy is based on the emotional processing theory
of PTSD and involves confrontation with distressing stimuli related to
the trauma and is continued until anxiety is reduced (Foa et al., 2008).
Imaginal exposure uses mental imagery from memory or introduced
in scenes presented to the patient by the therapist. In some cases,
exposure is to the actual scene or similar events in life: in vivo exposure
involves confronting real life situations that provoke anxiety and are
avoided because of their association with the traumatic event
(e.g., avoidance of tall buildings following experiencing an earthquake).
The aim is to extinguish the conditioned emotional response to trau-
matic stimuli. By learning that nothing “bad”will happen during a trau-
matic event, the patient experiences less anxiety when confronted by
stimuli related to the trauma and reduces or eliminates avoidance of
feared situations. Exposure therapy is typically conducted for 8 to 12
weekly or biweekly sessions lasting 60 to 90 min (Committee on
Treatment of Posttraumatic Stress Disorder, & Institute of Medicine,
2008; Foa et al., 2008; Wood et al., 2009). Prolonged exposure is a
manualized intervention including both imaginal and in vivo exposure
components (Foa et al., 2005).
In this report, we include a category for CBT-mixed therapies for
studies of interventions that use components of CBT, but that don't
quite fit cleanly into one of the other categories. The interventions in
this category are somewhat heterogeneous in several ways, including
how the authors defined and described “cognitive behavioral therapy.”
Elements of CBT-mixed interventions may include psychoeducation,
self-monitoring, stress management, relaxation training, skills training,
exposure (imaginal, in vivo, or both), cognitive restructuring, guided
imagery, mindfulness training, breathing retraining, crisis/safety
planning, and relapse prevention. The studies varied as to how many
sessions (if any) were dedicated to these elements and whether home-
work was assigned as part of the intervention.
In EMDR the patient is asked to hold the distressing image in mind,
along with the associated negative cognition and bodily sensations,
while engaging in saccadic eye movements. After approximately 20 s,
the therapist asks the patient to “blank it out,” take a deep breath, and
note any changes occurring in the image, sensations, thoughts, or
emotions. The process is repeated until desensitization has occurred
(i.e., patient reports little or no distress on the Subjective Units of
Distress Scale), at which time the patient is asked to hold in mind a
previously identified positive cognition, while engaging in saccadic
eye movements, and rating the validity of this cognition while goinglts with posttraumatic stress disorder: A systematic review andmeta-
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were initially theorized to both interfere with working memory and
elicit an orienting response, which lowers emotional arousal so that
the trauma can be resolved. Although earlier versions of EMDR
consisted of 1 to 3 sessions, current standards consist of 8 to 12 weekly
90-minute sessions (Committee on Treatment of Posttraumatic Stress
Disorder, & Institute of Medicine, 2008; Friedman, 2003).
Hypnosis may be used as an adjunct to psychodynamic, cognitive-
behavioral, or other therapies. It has been shown to enhance their effi-
cacy for many clinical conditions (Committee on Treatment of
Posttraumatic Stress Disorder, & Institute of Medicine, 2008; Foa et al.,
2008). Number and length of sessions vary widely.
Interpersonal therapy is a time-limited, dynamically informed psy-
chotherapy that aims to alleviate patients' suffering and improve their
interpersonal functioning. This type of therapy focuses specifically on
interpersonal relationships; its goal is to help patients either improve
their interpersonal relationships or change their expectations about
them. In addition, it aims to help patients improve their social support
so they can bettermanage their current interpersonal distress. Interper-
sonal therapy generally requires 10 to 20 weekly sessions in the “acute
phase” followed by a time-unlimited “maintenance phase” (Stuart,
2006).
Psychodynamic therapy explores the psychological meaning of a
traumatic event. The goal is to bring unconscious memories into
conscious awareness so that PTSD symptoms are reduced. The therapy
presumes that the PTSD symptoms are the result of the unconscious
memories. Psychodynamic therapy traditionally lasts from 3 months
to 7 years (Friedman, 2003).
Narrative exposure therapy is described as a standardized short-
term approach based on principles of exposure therapy that adapted ex-
posure therapy to meet the needs of traumatized survivors of war and
torture. The therapy has been applied to a number of civilian samples
who have experienced multiple traumatic events. NET is also based on
testimony therapy, where instead of defining a single traumatic event,
the patient constructs a narrative about their whole life from birth to
the present, while focusing on the detailed report of the traumatic
experiences (Neuner, Schauer, Klaschik, Karunakara, & Elbert, 2004).
A preliminary scheme for classifying psychological treatments for
PTSD was based on review of all of the articles on psychological
treatments that met inclusion criteria. Two investigators on our team
(KC and CAF) with expertise in cognitive behavioral interventions
assessed each psychological intervention in the included studies to
determine the most appropriate categorization of each intervention
based on the theoretical model and core components of the therapy.
The classification scheme and the categorization of each study was
then refined based on input by members of our technical expert panel,
peer reviewers, and public reviewers. We included a category for CBT-
mixed therapies for interventions that used various components of
CBT, but that were heterogeneous enough to prevent their inclusion
into one of the other categories.
Studies were required to assess at least one of the following out-
comes: PTSD symptoms, remission (no longer having symptoms), loss
of PTSD diagnosis, quality of life, disability or functional impairment,
return to work or active duty, or adverse events.
2.3. Data extraction and risk of bias assessment
Two investigators independently reviewed titles and abstracts for
study inclusion. Two investigators then independently reviewed the
full text of articles marked for possible inclusion to determine final in-
clusion/exclusion. If the reviewers disagreed, conflicts were resolved
with a third experienced team member. We designed and used struc-
tured forms to extract pertinent information fromeach article, including
information about the populations, interventions, comparators, out-
comes, timing, settings, and study designs. All data extractions were
reviewed for completeness and accuracy by a second team member.Please cite this article as: Cusack, K., et al., Psychological treatments for adu
analysis, Clinical Psychology Review (2015), http://dx.doi.org/10.1016/j.cprRisk of bias for each study was also determined independently by two
investigators; one of the two reviewers was always an experienced,
senior investigator. Disagreements between the two reviewers were
resolved by discussion and consensus or by consulting a third member
of the team. We excluded studies deemed high risk of bias from our
main data synthesis and main analyses; we included them only in
sensitivity analyses.
To assess the risk of bias of studies, we used predefined criteria
based on the AHRQ Methods Guide for Comparative Effectiveness
Reviews,(Viswanathan et al., 2012) rating studies as low, medium, or
high risk of bias.We includedquestions to assess selectionbias, confound-
ing, performance bias, detection bias, and attrition bias (i.e., those about
adequacy of randomization, allocation concealment, similarity of groups
at baseline, masking, attrition, whether intention to treat analysis was
used,method of handling dropouts andmissing data, validity and reliabil-
ity of outcome measures, and treatment fidelity).
In general terms, results from a study assessed as having low risk of
bias are considered to be valid. A studywithmoderate risk of bias is sus-
ceptible to some risk of bias but probably not enough to invalidate its re-
sults. A study assessed as high risk of bias has significant risk of bias
(e.g., stemming from serious issues in design, conduct, or analysis)
that may invalidate its results. We determined the risk of bias rating
via appraisal of responses to all 12 questions assessing the various
types of bias listed above. We did not use a quantitative approach
(e.g., adding up how many favorable or unfavorable responses were
given), but we did require favorable responses to at least 10 questions
to give a low risk of bias rating, with any unfavorable responses being
of relatively minor concern (e.g., lack of patient masking in studies
of psychological interventions, which is generally not considered
possible).
We gave high risk of bias ratings to studies that we determined to
have a fatal flaw (defined as a methodological shortcoming that leads
to a very high risk of bias) in one or more categories based on our qual-
itative assessment. Reasons for high risk of bias ratings included high
risk of selection bias due to inadequate method of randomization
(e.g., alternating) and resulting baseline differences between groups
with no subsequent approach to handle potential confounders, attrition
≥40% or differential attrition ≥30%, risk of attrition bias (attrition over
20% or differential attrition over 15%) along with inadequate handling
of missing data (e.g., completers analysis with nothing done to address
missing data), and other combinations of multiple risk of bias concerns.
Themajority of studies thatwe rated as high risk of bias had numer-
ous problems. On average, they received unfavorable responses to 8 of
our specific risk of bias assessment questions. Each of the studies rated
as high risk of bias had unfavorable responses to 5 or more questions.
The most common methodological shortcomings contributing to high
risk of bias ratings were high rates of attrition or differential attrition,
inadequate methods used to handle missing data, and lack of
intention-to-treat analysis.
2.4. Data synthesis and analysis
We used random effects models to conduct meta-analyses of out-
comes reported bymultiple studies thatwere sufficiently homogeneous
to justify combining their results (Sutton, Abrams, Jones, et al., 2000).
For continuous outcomes, we report the weighted mean difference
(WMD) between intervention and control or the standardized mean
difference (SMD), Cohen's d (when multiple scales were combined in
onemeta-analysis). For binary outcomes, we calculated risk differences
between groups and we calculated numbers needed to treat (NNTs)
when pooled risk differences found a statistically significant result. In
this context, the NNT represents the number of patients with PTSD
who need to be treated to achieve one good outcome (e.g. to achieve
loss of PTSD diagnosis), which is calculated as 1/Absolute Risk
Reduction. The chi-squared statistic and the I2 statistic were calculated
to assess statistical heterogeneity in effects between studies (Higginslts with posttraumatic stress disorder: A systematic review andmeta-
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quantitative analyses were not appropriate (e.g., because of clinical
heterogeneity, insufficient numbers of similar studies, or insufficiency
or variation in outcome reporting), we synthesized data qualitatively.
Pairwise meta-analyses were conducted using Stata version 11.1
(StataCorp LP, College Station, TX).
We graded the strength of evidence (SOE) as high,moderate, low, or
insufficient based on guidance established for the Evidence-based Prac-
tice Center Program (Table S2) (Owens et al., 2010). Developed to grade
the overall strength of a body of evidence, the approach incorporates
four key domains: risk of bias, consistency, directness, and precision of
the evidence. It also considers optional domains, such as strength of
association (a large magnitude of effect can increase the SOE). Two re-
viewers assessed each key domain for each outcome, and differences
were resolved by consensus.We graded the SOE as high when our as-
sessments for all key domains were favorable. For each key domain
with an unfavorable assessment, we downgraded the SOE by at least
one category. For example, if evidence for a treatment was inconsistent
(e.g., studies with conflicting results) and the estimate of effect was
imprecise (e.g., confidence interval wide enough to contain clinically
distinct conclusions), we typically graded the SOE as low. Substantial
concerns related to a single domain (e.g., substantially high risk of
bias) can result in downgrading by more than a single SOE category.
3. Results
We included 64 randomized controlled trials (Fig. 1). Sample sizes
ranged from 10 to 563, and study duration ranged from 4 weeks to 2
years. Sixty trials evaluated psychological treatments, one (van der KolkFig. 1. Disposition of Articles Identified by Searches aPICOTS refers to population, int
Please cite this article as: Cusack, K., et al., Psychological treatments for adu
analysis, Clinical Psychology Review (2015), http://dx.doi.org/10.1016/j.cpret al., 2007) compared psychological and pharmacological treatments,
and three (Foa et al., 2013; Rothbaum et al., 2006; Schneier et al., 2012)
evaluated combinations of psychological and pharmacological treatments
comparedwith either one alone (Table S3). The included studies general-
ly enrolled people with severe PTSD andwith amean age in the 30s–40s.
3.1. Efficacy of psychological treatments
First, we examined studies with inactive comparison groups
(e.g., waitlist, usual care) to determine whether evidence supports the
efficacy of each type of intervention. We then examined studies with
active comparison groups (i.e., head-to-head comparative evidence) to
address questions regarding comparative effectiveness. Findings are
presented below, and are summarized in Table 2.
3.2. Cognitive therapy
Evidence supports the efficacy of cognitive therapy, including cogni-
tive processing therapy, for improving PTSD symptoms, achieving loss
of PTSDdiagnosis, improvingdepression and anxiety symptoms, and re-
ducing disability for adults with PTSD (moderate SOE, Fig. 2). For
achieving loss of diagnosis, 50% more subjects treated with cognitive
therapy than subjects in control groups achieved the outcome. This
translates to a number needed to treat (NNT) of 2. For CPT in particular,
44% more subjects treated with this modality than subjects in the con-
trol group achieved loss of diagnosis, translating to a NNT of 2. Evidence
was insufficient for remission and for other outcomes (such as anxiety
symptoms, quality of life, disability or functioning, and return to work
or active duty) for CPT.ervention, comparators, outcome measures, timing, settings and study designs.
lts with posttraumatic stress disorder: A systematic review andmeta-
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Table 2
Summary of findings and strength of evidence for efficacy of psychological treatments.
Intervention Outcome Results Effect size (95% CI)a Strength of evidence
Cognitive processing therapy PTSD symptoms SMD−1.40 (−1.95 to−0.85, 4 trials, N = 299)
WMD−32.2 (−46.3 to−18.05, 4 trials, N = 299)
Moderate
Loss of diagnosis 0.44 (0.26 to 0.62, 4 trials, N = 299); NNT 3 Moderate
Depression symptoms WMD−10.7 (−16.5 to−4.9, 4 trials, N = 299) Moderate
Cognitive therapyb PTSD symptoms SMD−1.33 (−1.99 to−0.67; 4 trials, N = 282) Moderate
Loss of diagnosis 0.56 (0.32 to 0.79; 4 trials, N = 221); NNT 2 Moderate
Depression symptoms SMD−0.91 (−1.20 to−0.62; 3 trials, N = 221) Moderate
Cognitive therapy combined PTSD symptoms SMD−1.36 (−1.77 to−0.94; 9 trials, N = 604) Moderate
Loss of diagnosis 0.50 (0.36 to 0.64; 9 trials, N = 604); NNT 2 Moderate
Depression symptoms SMD−0.96 (−1.23 to−0.69; 9 trials, N = 604) Moderate
CBT—Exposure PTSD symptoms SMD−1.27 (−1.54 to−1.00, 7 trials, N = 387)
WMD−28.9 (−35.5 to−22.3, 4 trials, N = 212)
High
Loss of diagnosis 0.66 (0.42 to 0.91, 3 trials, N = 197); NNT 2 Moderate
Depression symptoms WMD−8.2 (−10.3 to−6.1, 6 trials, N = 363) High
CBT—Mixed (CBT-M) PTSD symptoms SMD−1.09 (−1.4 to−0.78, 14 trials, N = 825)
WMD−31.1 (−42.6 to−19.6, 8 trials, N = 476)
Moderate
Loss of diagnosis 0.26 (0.11 to 0.41, 6 trials, N = 290); NNT 4 Moderate
Depression symptoms WMD−10.4 (−14.4 to−6.4, 10 trials, N = 662) Moderate
EMDR PTSD symptoms SMD−1.08 (−1.83 to−0.33, 4 trials, N = 117) Low
Loss of diagnosis 0.64 (0.46 to 0.81, 3 trials, N = 95); NNT 2 Moderate
Depression symptoms SMD−1.13 (−1.52 to−0.74, 4 trials, N = 117) Moderate
Narrative exposure therapy (NET) PTSD symptoms SMD−1.25 (−1.92 to−0.58, 3 trials, N = 227)
PDS, WMD−10.2 (−13.1 to−7.4, 3 trials, N = 227)
Moderate
Loss of diagnosis 0.15 (0.01 to 0.30, 3 trials, N = 227) Low
Depression symptoms Mixed evidence; 1 trial reported efficacy and 1 reported no
difference from comparators, 2 trials, N = 75
Insufficient
Brief eclectic psychotherapy (BEP) PTSD symptoms Likely small-to-medium effect size (3 trials, N = 96) Low
Loss of diagnosis RD ranged from 0.125 to 0.58 across trials (3 trials, N = 96) Low
Depression symptoms 3 trials (N = 96) found benefits, wide range of effect sizes in the
2 trials reporting sufficient data, frommedium to very large
Low
CI= confidence interval; EMDR= EyeMovement Desensitization and Reprocessing; N= number of subjects; NNT=number needed to treat; NR= not reported; NS= not statistically
significant; PDS = Posttraumatic Diagnostic Scale; RD = risk difference; SOE = strength of evidence; WMD=weighted mean difference.
a WMDdata for PTSD symptoms aremean change from baseline (95% CI, number of trials and number of subjects contributing data) in CAPS score comparedwith inactive comparators
unless another outcome measure is specified; SMD data are Cohen's d—effect sizes. A small effect size is d = 0.20, medium effect size is d = 0.50, and large effect size is d = 0.80. (41)
NegativeWMDs and SMDs favor the intervention.Using CAPS, PTSD severity has been categorized as asymptomatic/few symptoms (0 to 19),mild PTSD/subthreshold (20 to 39),moderate
PTSD/threshold (40 to 59), severe (CAPS of 60–79), and extreme (CAPS ≥80). (42) Baseline PTSD severity was generally in the severe or extreme range across the included trials. Data for
loss of diagnosis are risk difference for treatment comparedwith inactive comparators unless otherwise specified; positive numbers favor the intervention.WMDdata for depression symptoms
are mean change from baseline in BDI score compared with inactive comparators unless another outcome measure is specified. SMD data for depression symptoms are Cohen's d.
b For the purposes of summarizing results and conclusions, the cognitive therapy category here summarizes evidence from the cognitive therapy studies that were not specifically
cognitive processing therapy.
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Evidence was insufficient to determine efficacy of relaxation or
stress inoculation training for adults with PTSD. One trial comparing
prolonged exposure, stress inoculation training, prolonged exposure
plus stress inoculation training, andwaitlist suggests that stress inocula-
tion training may be efficacious (Foa et al., 2005).
3.4. Exposure therapy
Evidence supports the efficacy of exposure therapy for improving
PTSD symptoms (high SOE, Fig. 3), achieving loss of PTSD diagnosis
(moderate SOE), and improving depression symptoms for adults with
PTSD (high SOE). For achieving loss of PTSD diagnosis, 66% more sub-
jects treated with exposure than subjects in waitlist control groups
achieved the outcome. This translates to a NNT of 2. Evidencewas insuf-
ficient for other outcomes (remission, anxiety, quality of life, disability
or functional impairment, and return to work or active duty). With
the exception of one study (Basoglu, Salcioglu, & Livanou, 2007) the ef-
ficacy evidence comes from trials of Prolonged Exposure, a manualized
therapy combining imaginal and in vivo exposure.
3.5. CBT-mixed
Evidence supports the efficacy of CBT-mixed treatments for improving
PTSD symptoms (moderate SOE). Evidence also supports the efficacy of
CBT-mixed interventions for achieving loss of PTSD diagnosis (moderate
SOE), remission (moderate SOE), reduction of depression symptomsPlease cite this article as: Cusack, K., et al., Psychological treatments for adu
analysis, Clinical Psychology Review (2015), http://dx.doi.org/10.1016/j.cpr(moderate SOE), reduction of disability or functional impairment (low
SOE), and anxiety symptoms (low SOE). For achieving loss of diagnosis,
26% more subjects treated with CBT-mixed therapies than subjects in in-
active control groups achieved the outcome. This translates to a NNT of 4
(Fig. 4).
3.6. Eye movement desensitization and reprocessing (EMDR)
Evidence supports the efficacy of EMDR for reduction of PTSD symp-
toms, but SOE is low because of some inconsistency and imprecision.
Evidence supports the efficacy of EMDR for achieving loss of PTSD diag-
nosis and improving depression symptoms (moderate SOE for both);
64% more subjects treated with EMDR experienced this outcome than
did subjects in waitlist control groups. This translates to a NNT of 2.
Evidence was insufficient to determine efficacy of EMDR for other
outcomes (remission, anxiety, quality of life, disability or functioning,
and return to work or active duty) (Fig. 5).
3.7. Other psychological therapies
Evidence supports the efficacy of NET for improving PTSD symptoms
(moderate SOE, Fig. 6) and for achieving loss of PTSD diagnosis (low
SOE). Some evidence supports the efficacy of brief eclectic psychother-
apy for improving PTSD symptoms, achieving loss of diagnosis, reducing
depression and anxiety symptoms, and returning towork (all low SOE).
Evidence was insufficient to determine the efficacy of Seeking Safety
(Hien, Cohen, Miele, Litt, & Capstick, 2004), COPE (Mills et al., 2012),
or imagery rehearsal therapy (Krakow et al., 2001).lts with posttraumatic stress disorder: A systematic review andmeta-
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remission for all psychological treatments except for CBT-mixed
treatments (moderate SOE), because trials typically did not report remis-
sion as an outcome. Similarly, evidence for improving anxiety symptoms,
quality of life, disability or functional impairment, or return to work or
active duty was generally insufficient (often with no trials reporting
those outcomes) with a few exceptions: some evidence supported effica-
cy of cognitive therapy for improving anxiety symptoms and disability
(moderate SOE), efficacy of CBT-mixed treatments and brief eclectic psy-
chotherapy for improving anxiety symptoms (lowSOE), CBT-mixed treat-
ments for improving disability and functional impairment (low SOE), and
brief eclectic psychotherapy for improving return to work (low SOE).3.8. Comparative effectiveness of treatments
Most of the head-to-head evidence was insufficient to determine
ifpsychotherapies differ in effectiveness (Table 3), with a few excep-
tions. There was moderate strength of evidence to suggest that expo-
sure therapy was superior to relaxation for reducing PTSD symptoms.Table 3
Summary of findings and strength of evidence for comparative effectiveness of psychological t
Comparison Outcome Results E
CR vs. Relaxation PTSD symptoms 50% vs. 2
Loss of diagnosis 65% vs. 5
Depression symptoms 7 (3 to 1
CT vs. Exposure PTSD symptoms WMD 4.
Loss of diagnosis RD 0.13
Depression symptoms WMD 2.
Exposure vs. CPT PTSD symptoms WMD 3.
Loss of diagnosis 0.00 (−
Depression symptoms WMD 2.
Exposure vs. Relaxation PTSD symptoms WMD−
Loss of diagnosis Favors e
Depression symptoms WMD−
Exposure vs. SIT PTSD symptoms SMD−0
Loss of diagnosis RD 0.18
Depression symptoms WMD−
Relaxation vs. EMDR PTSD symptoms SMD−0
Loss of diagnosis 0.34 (−
Depression symptoms Conflicti
Relaxation vs. CBT-M PTSD symptoms Favors C
Loss of diagnosis No inclu
Depression symptoms No inclu
Exposure vs. EMDR PTSD symptoms No diffe
Loss of diagnosis Both tria
statistica
RD 0.14
Depression symptoms No diffe
Exposure vs. Exposure plus CR PTSD symptoms SMD 0.2
Loss of diagnosis Similar b
Depression symptoms WMD 2.
Brief eclectic psychotherapy vs. EMDR PTSD symptoms 1 trial (N
EMDR, b
Loss of diagnosis 1 trial (N
EMDR, b
Depression symptoms 1 trial (N
EMDR, b
Seeking safety vs. active controlsc PTSD symptoms SMD 0.0
WMD 1.
Loss of diagnosis OR 1.22
Depression symptoms No trials
CI = confidence interval; CR = cognitive restructuring; EMDR= Eye Movement Desensitizati
significant; SIT = stress inoculation training; SOE = strength of evidence; WMD=weighted
Table only includes rows for comparisons with any available trials. We found no low or mediu
a For PTSD symptoms,WMDdata aremean change frombaseline (95%CI, number of trials an
unless another outcomemeasure is specified; SMD data are Cohen's d—effect sizes. Using CAPS,
subthreshold (20 to 39),moderate PTSD/threshold (40 to 59), severe (CAPS of 60 to 79), and ext
across the included trials. For loss of diagnosis, data are risk difference (95% CI, number of trials
unless otherwise specified. For depression symptoms,WMD data are between-group difference
SMD data for depression symptoms are Cohen's d.
b Mean CAPS improvement: 38 (95% CI, 26 to 50) vs. 14 (95% CI, 4 to 25) in one trial; (80) be
c Active controls were relapse prevention, psychoeducation, and treatment as usual in a VA
Please cite this article as: Cusack, K., et al., Psychological treatments for adu
analysis, Clinical Psychology Review (2015), http://dx.doi.org/10.1016/j.cprThere was moderate strength of evidence that exposure therapy and
cognitive therapy were similar in loss of PTSD diagnosis, and moderate
strength of evidence that Seeking Safety is more effective than sub-
stance abuse treatment as usual for improving PTSD symptoms.
One trial (N=88)meeting inclusion criteria compared a psycholog-
ical treatment (EMDR) with a pharmacological treatment (fluoxetine)
(van der Kolk, et al.). EMDR- and fluoxetine-treated subjects had similar
improvements in PTSD symptoms, rates of remission, and loss of PTSD
diagnosis at the end of treatment. At 6-month follow-up, those
treated with EMDR had higher remission rates and greater reductions
in depression symptoms comparedwith thosewho received fluoxetine.
But, this head-to-head evidence was insufficient to draw any firm con-
clusions about comparative effectiveness, primarily due to unknown
consistency (with data from just one study) and lack of precision.3.9. Adverse effects
The vast majority of studies did not report information about
adverse effects. A total of 17 studies reported any information onreatments.
ffect size (95% CI)a Strength of Evidence
0% of subjects improved, p = 0.04, 1 trial, N = 34 Insufficient
5% of subjects, p = NS, 1 trial, N = 34 Insufficient
1) vs. 17 (11 to 22), 1 trial, N = 34 Insufficient
8 (−4.5 to 14.2; 2 trials, N = 100) Insufficient
(−0.06 to 0.32; 2 trials, N = 100) Insufficient
75 (−1.94 to 7.43; 2 trials, N = 100) Insufficient
97 (−5.95 to 13.9; 1 trial, N = 124) Insufficient
0.18 to 0.18; 1 trial, N = 124) Insufficient
94 (−0.75 to 6.63; 1 trial, N = 124)
9.7 (−22.3, 2.9; 2 trials, N = 85) Insufficient
xposure: RD 0.31 (0.04, 0.58; 2 trials, N = 85) Moderate
5.5 (−10.2 to−0.79; 2 trials, N = 85) Moderate
.14 (−0.69 to 0.41; 1 trial, N = 51) Insufficient
(−0.09 to 0.45; 1 trial, N = 51) Insufficient
0.15 (−5.8 to 5.5; 1 trial, N = 51) Insufficient
.57 (−1.4 to 0.29; 2 trials, N = 64) Insufficient
0.04 to 0.72; 2 trials, N = 64) Insufficient
ng findings (2 trials, N = 64) Insufficient
BT-M (2 trials, N = 85)b Moderate
ded studies reported the outcome Insufficient
ded studies reported the outcome Insufficient
rence found (2 trials, N = 91) Insufficient
ls favor exposure, but meta-analysis did not find a
lly significant difference and results were imprecise:
(−0.01 to 0.29; 2 trials, N = 91)
Insufficient
rence (2 trials, N = 91) Insufficient
5 (−0.29 to 0.80; 3 trials, N = 259) Insufficient
enefits: RD -0.01 (−0.17 to 0.14; 3 trials, N = 259) Moderate
78 (−1.68 to 7.25; 4 trials N = 299) Insufficient
= 140) reported more rapid improvement with
ut no difference after completion of treatment
Insufficient
= 140) reported more rapid improvement with
ut no difference after treatment
Insufficient
= 140) reported more rapid improvement with
ut no difference after treatment
Insufficient
4 (−0.12 to 0.20; 4 trials, N = 594)
45 (−2.5 to 5.4; 3 trials, N = 477)
Moderate
(0.48 to 3.13; 1 trial, N = 49) Insufficient
Insufficient
on and Reprocessing; N = number of subjects; NR = not reported; NS = not statistically
mean difference.
m risk-of-bias trials making other head-to-head comparisons.
d number of subjects contributing data) in CAPS score comparedwith inactive comparators
PTSD severity has been categorized as asymptomatic/few symptoms (0 to 19), mild PTSD/
reme (CAPS ≥80). (42) Baseline PTSD severitywas generally in the severe or extreme range
and number of subjects contributing data) for the comparison between the two therapies
for mean change from baseline in BDI score unless another outcomemeasure is specified.
tween group effect size was very large favoring CBT-M (Cohen's d = 1.6) in another (70).
substance use disorders clinic.
lts with posttraumatic stress disorder: A systematic review andmeta-
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Fig. 2. Change in CAPS for cognitive therapy compared with control, by type of comparator.
9K. Cusack et al. / Clinical Psychology Review xxx (2015) xxx–xxxadverse events. Three CBT-mixed, one PE, one COPE, and one
EMDR study reported withdrawals from the study due to adverse
effects (Blanchard et al., 2003; Cottraux et al., 2008; Foa et al.,
2013; Hogberg et al., 2007; Hollifield, Sinclair-Lian, Warner, &
Hammerschlag, 2007; Sannibale et al., 2013). Two cognitive therapyFig. 3.Mean change from baseline to end of treatment in PTSD symptoms (any m
Please cite this article as: Cusack, K., et al., Psychological treatments for adu
analysis, Clinical Psychology Review (2015), http://dx.doi.org/10.1016/j.cprand two “other” psychological interventions reported that there
were no treatment-related adverse events (Boden et al., 2012;
Ehlers et al., 2014; Forbes et al., 2012; Ford, Steinberg, & Zhang,
2011). Three studies reported deaths due to medical illness that
were unrelated to the intervention (Foa et al., 2005; Schnurr et al.,easure) for exposure therapy compared with control, by type of comparator.
lts with posttraumatic stress disorder: A systematic review andmeta-
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Fig. 4.Mean change from baseline to end of treatment in PTSD symptoms for CBT-mixed compared with control, by type of comparator.
10 K. Cusack et al. / Clinical Psychology Review xxx (2015) xxx–xxx2007; Schnurr et al., 2003) three studies reported on suicide
attempts (N = 1 in PE condition and N = 3 in PCT condition), com-
pleted suicide (N = 1 in PCT), and hospital admissions for serious
suicidal ideation (N = 2 in NET group) (Neuner et al., 2010;Fig. 5.Mean change from baseline to end of treatment in PTSD symp
Please cite this article as: Cusack, K., et al., Psychological treatments for adu
analysis, Clinical Psychology Review (2015), http://dx.doi.org/10.1016/j.cprSchnurr et al., 2007; Schnurr et al., 2003). Evidence was insufficient
to draw conclusions about withdrawals due to adverse events, mor-
tality, suicide, suicidal ideation, self-harmful behaviors, or other spe-
cific adverse events.toms for EMDR compared with control, by type of comparator.
lts with posttraumatic stress disorder: A systematic review andmeta-
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Fig. 6.Mean change from baseline to end of treatment in PTSD symptoms for NET compared with control.
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The sensitivity analyses including studies rated as high risk of bias
did not produce significantly different results; point estimates and
confidence intervals were generally very similar, and the sensitivity
analyses did not alter any of our main conclusions.
4. Discussion
Our meta-analysis demonstrates efficacy of exposure therapy
(including prolonged exposure) for improving PTSD symptoms (high
SOE), and for number needed to treat and loss of diagnosis (moderate
SOE). Evidence also supports efficacy of cognitive therapy, including
CPT, and CBT-mixed therapies, (moderate SOE for all), eye movement
desensitization and reprocessing (EMDR) (low SOE for PTSD symptom
reduction, moderate SOE for loss of diagnosis) and NET (moderate
SOE for PTSD symptom reduction, low SOE for loss of diagnosis). Effect
sizes were large and the NNT was ≤4 for each of these therapies.
Head-to-head comparative effectiveness evidence was limited.
The magnitude of benefit and SOE for exposure therapy supports its
use as a first-line treatment for PTSD. However, other factors must be
considered in selecting a treatment for PTSD, including patient prefer-
ence, access to treatment, and clinical judgment about the appropriate-
ness of an intervention. For instance, exposure therapy and CPT are now
readily available in most VAMC outpatient settings, but are less likely to
be available in community-based mental health centers. A majority of
the studies we reviewed excluded patients with substance dependence
or suicidality. Most clinicians would agree that stabilization of
suicidality and, at a minimum, detoxification from substances should
occur prior to initiating a trauma-focused psychotherapy such as expo-
sure therapy. There is less consensus onwhether substance use disorder
therapy should be integrated with PTSD therapy or conducted prior to
or concomitantly with PTSD therapy, although emerging research
shows promise for integrated therapies (Mills et al., 2012; Sannibale
et al., 2013). Given themagnitude of benefit and SOE for cognitive ther-
apy (including CPT), CBT-mixed, NET, and EMDR, we recommend that
these therapies should also be considered based on the above consider-
ations. Our review did not identify studies that inform matching
patients to treatment, consistent with the findings of a recent study of
moderators for the treatment of anxiety disorders (Schneider, Arch, &
Wolitsky-Taylor, 2015).
Consistent with existing guidelines and systematic reviews, our
findings indicate that there are efficacious psychological treatments
for PTSD. We reached a few notably different conclusions thanPlease cite this article as: Cusack, K., et al., Psychological treatments for adu
analysis, Clinical Psychology Review (2015), http://dx.doi.org/10.1016/j.cprthose presented in the IOM report (Committee on Treatment of
Posttraumatic Stress Disorder, & Institute of Medicine, 2008). First, we
concluded that CPT has moderate evidence supporting efficacy for
improving some outcomes for adults with PTSD, whereas the IOM
report did not make a specific conclusion about CPT. We believe this
differencewas due tomisclassification (in the IOM report) of three trials
of CPT that provided the bulk of the evidence supporting the efficacy of
CPT. The IOM report classified these three trials as exposure therapy
whereas we classified them as cognitive therapy. Although the current
version of CPT includes components that are similar to exposure thera-
py, we classified CPT as cognitive therapy because the therapy is based
on social-cognitive theory, the core components are classic cognitive
therapy techniques, and dismantling studies of CPT do suggest a critical
contribution of the cognitive components (Resick et al., 2008). Second,
we concluded that evidence supports the efficacy of EMDR (low SOE
for PTSD symptom reduction and moderate SOE for loss of diagnosis)
whereas the IOM report indicated that evidence was inadequate to
determine EMDR's efficacy. We likely reached a different conclusion
because we synthesized the data quantitatively (with meta-analysis)
rather than qualitatively — increasing precision and ability to find a
difference. Finally, our conclusions differ from those of the APA and
the ISTSS guidelines regarding stress inoculation training. We deter-
mined that there was insufficient evidence to determine its efficacy
based on one medium risk of bias trial (N = 41 total subjects in the
stress inoculation training and waitlist arms, combined), and one
study we rated high risk of bias (N = 27 total subjects in the stress
inoculation training and waitlist arms, combined). Further, the APA
used a different approach to data synthesis (qualitative rather than
quantitative) and relied more on expert opinion to develop guidelines.
4.1. Applicability of findings
Studies generally enrolled subjects from outpatient settings with se-
vere (60–79 CAPS score) to extreme (≥80 CAPS score) PTSD symptoms.
Most studies included participants with chronic PTSD (i.e., symptoms
lasting at least threemonths). However, studies inconsistently reported,
and had wide variation in, the time between the occurrence of the
traumatic event and trial entry. The mean age of subjects was generally
in the 30s to 40s, but some studies enrolled slightly older populations.
We found studies of people with a wide range of trauma exposures,
andmany studies enrolled a heterogeneous group of subjects with a va-
riety of index trauma types. Evidence was insufficient to determine
whether findings are applicable to all those with PTSD or whether
they are only applicable to certain groups. Our review was unable tolts with posttraumatic stress disorder: A systematic review andmeta-
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variables, such as gender or age, on treatment efficacy. This question
could be of great benefit to clinicians attempting to recommend a
therapy for an individual patient, and future studies should attempt to
address this.
We recognize the hypothesis that treatments proven to be effective
for adults with PTSD should be applicable to all adults with PTSD, but
we did not find evidence to confirm or refute this hypothesis. For exam-
ple, there was often very little evidence from subjects with combat-
related trauma that contributed to assessments of the efficacious
treatments—making it difficult to determine with any certainty wheth-
er or not findings are applicable to adults with PTSD from combat-
related trauma. In addition, just one included trial for each of
the following treatments focused on combat-related trauma: EMDR
(N = 35),(Carlson, Chemtob, Rusnak, Hedlund, & Muraoka, 1998)
CBT-mixed (N = 45),(Litz, Engel, Bryant, & Papa, 2007). For each of
the following, two trials focused on combat-related trauma: CPT (total
N = 119) (Forbes et al., 2012; Monson et al., 2006), exposure-based
therapy (total N = 370) (Gamito et al., 2010; Schnurr et al., 2003);
another study of exposure-based therapy enrolled those with combat-
and terror-related PTSD) (Nacasch et al., 2011).
4.2. Limitations
Determining the classification of psychological treatments was
sometimes challenging. We recognize that experts in psychological
treatments sometimes disagree about how to best categorize interven-
tions. Some of the findings might have been slightly different if the psy-
chological treatments were classified differently. Our approach to
classifying and categorizing psychological treatments relied on the the-
oretical model guiding the therapy as well as the core therapy compo-
nents. Categorization was based on independent review by two
investigators with relevant expertise and informed by technical expert
panel and reviewer feedback. Our exposure therapy category lumps
studies using various types of exposure therapy. The vast majority of
these studies that contributed data to our meta-analyses evaluated
prolonged exposure; thus the findings for exposure therapy are largely
driven by studies of prolonged exposure. All but one study included in
this category evaluated prolonged exposure; the other study evaluated
in vivo exposure alone. Analyses with and without the in vivo study
were virtually identical.
Many of the trials assessing treatments for adults with PTSD had
methodological limitations introducing some risk of bias. We excluded
30 articles from our main data synthesis because of high risk of bias.
High risk of biaswasmost frequently due to high rates of attrition or dif-
ferential attrition and inadequate methods used to handle missing data.
High attrition rates are not uncommon in studies of psychiatric condi-
tions (Gartlehner et al., 2011; Khan, Khan, Leventhal, & Brown, 2001a,
2001b). It is unknown to what extent the attrition rates were due to
the underlying condition—given that some of the key features of PTSD
are avoidance, loss of interest, and detachment—or to the treatments
(e.g., adverse effects, worsening of symptoms). Another common
methodological limitation was the lack of masking of outcome assessors.
4.3. Conclusions and future directions
Several psychological treatments have evidence of at least moderate
strength supporting their efficacy for improving outcomes for adults
with PTSD. Effect sizes for PTSD symptom reduction were large for
exposure-based therapy, CPT, cognitive restructuring, CBT-mixed thera-
pies, NET, and EMDR. Head-to-head evidence was insufficient to deter-
mine the comparative effectiveness of these treatments. Future studies
should compare interventions with demonstrated efficacy. Evidence
was generally insufficient to determine whether any treatment
approaches are more or less effective for particular groups of people.
Future studies should examine moderators of treatment efficacy andPlease cite this article as: Cusack, K., et al., Psychological treatments for adu
analysis, Clinical Psychology Review (2015), http://dx.doi.org/10.1016/j.cprexamine patient preferences. Evidence was insufficient to determine
comparative risks of adverse effects. Thus far we have identified a
number of efficacious psychological therapies in the treatment of
PTSD. Beyond efficacy, it is important to understand the tolerability
and potential adverse effects of an intervention, especially when
making a choice between medication and psychotherapy. We strongly
recommend that this information be reported on PTSD therapy trials
to better understand the potential harmful effects of treatment.
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TABLE S1. Questions for the Full Technical Report for the Effective Healthcare 
Program of the Agency for Healthcare Research and Quality 
1 What is the comparative effectiveness of different psychological treatments for adults diagnosed 
with PTSD? 
2 What is the comparative effectiveness of different pharmacological treatments for adults 
diagnosed with PTSD? 
3 What is the comparative effectiveness of different psychological treatments versus 
pharmacological treatments for adults diagnosed with PTSD? 
4 How do combinations of psychological treatments and pharmacological treatments (e.g., CBT plus 
paroxetine) compare with either one alone (i.e., one psychological or one pharmacological 
treatment)? 
5 Are any of the treatment approaches for PTSD more effective than other approaches for victims of 
particular types of trauma? 
6 What adverse effects are associated with treatments for adults diagnosed with PTSD? 
  
2 
 
Supplementary Methods. Methodology and WinBUGS Code Used in Our Network Meta-
Analysis 
We used the methodology and WinBUGS code described in the NICE Evidence Synthesis Technical Support 
Document 2,(Dias, Welton, Sutton, & Ades, 2011) which details the generalized linear modeling (GLM) framework 
for conducting a network meta-analysis of randomized controlled trials. Given the continuous nature of our outcome 
measure, the GLM model was fit with a normal likelihood and identity link function. We used a random effects 
model that adjusted for correlations between arms within each study, and study effect and treatment effect 
parameters were modeled by vague (flat) prior distributions that were Normal (0, 10000). For the between-trial 
variance, we used a uniform prior distribution centered at zero with sufficiently large variance. The first 20,000 
simulations were discarded to allow for model convergence and then a further 80,000 simulations were used in 
estimating the posterior probabilities. Satisfactory convergence was verified by trace plots and calculation of the 
Monte Carlo error for each parameter. No inconsistencies in the network were detected, and to minimize between-
trial heterogeneity, we assessed the clinical and methodological heterogeneity of the studies in the analysis 
following established guidance.(West et al., 2010) The WinBUGS code used to conduct the MTC meta-analysis is 
given below. WinBUGS Version 1.4.3 was used for all analyses.  
Random Effects Model for Continuous Outcome Data  
# Normal likelihood, identity link 
# Random effects model for multi-arm trials 
 
model{                               # *** PROGRAM STARTS 
 
for(i in 1:ns){                      #   LOOP THROUGH STUDIES 
    w[i,1] <- 0    # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0             # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,.0001)           # vague priors for all trial baselines 
    for (k in 1:na[i]) {             #  LOOP THROUGH ARMS 
        var[i,k] <- pow(se[i,k],2)   # calculate variances 
        prec[i,k] <- 1/var[i,k]      # set precisions 
        y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # binomial likelihood 
        theta[i,k] <- mu[i] + delta[i,k]  # model for linear predictor 
#Deviance contribution 
        dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k] 
      } 
#  summed residual deviance contribution for this trial 
    resdev[i] <- sum(dev[i,1:na[i]])        
    for (k in 2:na[i]) {             # LOOP THROUGH ARMS 
# trial-specific LOR distributions 
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        delta[i,k] ~ dnorm(md[i,k],taud[i,k]) 
# mean of LOR distributions, with multi-arm trial correction 
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] 
# precision of LOR distributions (with multi-arm trial correction) 
        taud[i,k] <- tau *2*(k-1)/k 
# adjustment, multi-arm RCTs 
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) 
# cumulative adjustment for multi-arm trials 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1) 
      } 
  }    
totresdev <- sum(resdev[])            #Total Residual Deviance 
d[1]<-0       # treatment effect is zero for control arm 
# vague priors for treatment effects 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } 
sd ~ dunif(0,5)     # vague prior for between-trial SD 
tau <- pow(sd,-2)   # between-trial precision = (1/between-trial variance) 
 
# All pairwise comparisons 
for (c in 1:(nt-1)) {  for (k in (c+1):nt)  { diff[c,k] <- (d[c] - d[k] )}} 
}                                     # *** PROGRAM ENDS                                                                               
 
WinBUGS Dataset  
#Description of data inputs 
#ns = Number of studies 
#nt = Number of treatments (including placebo) 
#t[,x] = Treatment indicator 
#y[,x] = Mean change from baseline in CAPS Total score   
#se[,x]= Standard error of mean change from baseline in CAPS Total score   
#na[] = Number of arms in study 
 
list(ns=28, nt=14)    
 
t[,1] t[,2] t[,3] y[,1] y[,2] y[,3] se[,1] se[,2] se[,3] na[] 
1   2   NA   -16.99   -12.33   NA   3.5607   5.6851   NA   2 
1   3   11   -38.7   -30.72   -41.82   8.0037   4.556   5.2817   3 
1   5   NA   -16.5   -15.1   NA   3.6112   3.3211   NA   2 
1   6   6   -36.6   -42.9   -42.8   2.7396   1.8093   2.2057   3 
1   6   NA   -26.8   -34.6   NA   3.0138   1.8692   NA   2 
1   6   NA   -26.75   -31.03   NA   3.6489   3.5219   NA   2 
1   6   NA   0   -12.59   NA   4.2028   4.0734   NA   2 
1   7   NA   -2.67   -14.8   NA   3.5167   4.4778   NA   2 
1   8   8   -25.3   -39.6   -37.9   1.8817   1.8744   2.0988   3 
1   8   NA   -24.7   -35.5   NA   1.9748   1.9253   NA   2 
1   9   NA   -7   -13   NA   4.9229   5.1105   NA   2 
1   9   NA   2.9   -21.8   NA   11.677   12.515   NA   2 
1   10   NA   -4.6   -14.3   NA   2.3335   2.9071   NA   2 
1   10   NA   -11.04   -13.77   NA   1.3   1.27   NA   2 
1   10   NA   -10.1   -9   NA   4.3063   5.4188   NA   2 
1   10   NA   -18.6   -29.6   NA   4.1   9.0933   NA   2 
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1   11   14   -34.17   -39.44   -41.5   2.0865   2.1577   2.1173   3 
1   11   NA   -26.2   -33   NA   2.2574   2.38   NA   2 
1   11   NA   -32.7   -32.56   NA   4.2858   2.2414   NA   2 
1   11   NA   -13.5   -18.7   NA   1.5141   1.397   NA   2 
1   11   NA   -15.4   -13.1   NA   3.0997   2.9999   NA   2 
1   11   NA   -23.2   -33   NA   2.9004   2.8003   NA   2 
1   12   NA   -30.2   -30.7   NA   2.4419   2.3305   NA   2 
1   13   NA   -42   -52.7   NA   14.41   18.92   NA   2 
1   13   NA   -30.36   -48.35   NA   7.0232   6.526   NA   2 
1   13   NA   -2.28   -17.95   NA   1.5615   1.3651   NA   2 
1   14   NA   -44.8   -51.8   NA   1.9882   1.7855   NA   2 
4   8   NA   -33.22   -36.44   NA   5.3794   4.8915   NA   2 
END 
 
#Initial Values  
#chain 1 
list(d=c( NA,0,0,0,0,0,0,0,0,0,0,0,0,0), sd=1,  
mu=c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 
           0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 
 0, 0, 0, 0, 0, 0, 0,0)) 
   
#chain 2 
list(d=c( NA, -1, -3, -1, 1, 3, -1, 1, -3, 1, -1, 3, 1, -3), sd=4,  
mu=c(-3, -3, -3, -3, -3, -3, -3, -2, -3, -3, 
           -3, -3, -3, -3, -3, -3, -3, -2, -3, -3, 
-3, -3, -3, -3, -3, -3, -3, -3)) 
 
#chain 3 
list(d=c( NA, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2,2), sd=2,  
mu=c(-3, 5, -1, -3, 7, -3, -4, 
-3, 5, -1, -3, 7, -3, -4, 
-3, 5, -1, -3, 7, -3, -4, 
-3, 5, -1, -3, 7, -3, -4)) 
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TABLE S2. Definitions of the Grades of Overall Strength of Evidence (Owens et 
al., 2010) 
Grade Definition 
High High confidence that the evidence reflects the true effect. Further research is 
very unlikely to change our confidence in the estimate of effect. 
Moderate Moderate confidence that the evidence reflects the true effect. Further 
research may change our confidence in the estimate of the effect and may 
change the estimate. 
Low Low confidence that the evidence reflects the true effect. Further research is 
likely to change our confidence in the estimate of the effect and is likely to 
change the estimate. 
Insufficient Evidence either is unavailable or does not permit estimation of an effect. 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments 
Study Arm (N) 
Duration 
(Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age (y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
Asukai et al., 
2010(Asukai
, Saito, 
Tsuruta, 
Kishimoto, & 
Nishikawa, 
2010) 
PE (12) 
UC (12) 
8 to 15 weekly 
sessionsb (3 mths, 
6 mths, 12 mths) 
Male & Female 
Mixed 
84.3 to 84.6 29 
 
88 100 Medium 
Basoglu et 
al., 
2007(Basogl
u, Salcioglu, 
& Livanou, 
2007) 
In vivo (16) 
WL (15) 
1 sessionb (4 wks, 
8 wks, 12 wks, 24 
wks, 1 year) 
Male & Female 
Natural Disaster 
62.3 to 63.1 34 87 NR Medium 
Blanchard et 
al., 
2003(Blanch
ard et al., 
2003) 
CBT-M (27) 
SC (27) 
WL (24) 
8 to 12 weeks (3 
mths) 
Male & Female 
MVA 
65.0 to 68.2 41 73 10 Medium 
Boden et al., 
2012(Boden 
et al., 2012) 
SS (59) 
TAU (58) 
12 weeks Male 
Combat 
IES-R 
46.8 to 47.7 
54 0 74 Medium 
Bryant et al., 
2003(Bryant, 
Moulds, 
Guthrie, 
Dang, & 
Nixon, 2003) 
IE (20) 
CBT-M 
(Imaginal+CR) (20) 
SC (18) 
8 weeks Male & Female 
Mixed 
CAPS-I 
intensity 
32.5 to 32.9 
 
35 52 NR Medium 
Bryant et al., 
2008(Bryant 
et al., 2008) 
PE (31) 
CBT-M (PE+CR) (28) 
IE (31) 
In vivo exp (28) 
8 weeks Male & Female 
Mixed 
71.4 to 76.8 37 NR 8 
 
Medium 
Carlson et 
al., 
Relax (13) 
EMDR (10) 
6 weeks (3 mths,9 
mths) 
Male 
Vietnam combat 
M-PTSD 
117.5 to 119.4 
49 0 46 Medium 
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1998(Carlso
n, Chemtob, 
Rusnak, 
Hedlund, & 
Muraoka, 
1998) 
TAU (12) veterans 
Chard et al., 
2005(Chard, 
2005) 
CPT (36) 
MA (35) 
17 weeks (3 
mths,12 mths) 
Female 
Childhood sexual 
abuse 
65.5 to 68.3 33 100 19 Medium 
Cloitre et al., 
2002(M. 
Cloitre, 
Koenen, 
Cohen, & 
Han, 2002) 
CBT-M (31) 
WL (27) 
12 months Female 
Childhood abuse 
69 
 
34 100 54 Medium 
Cloitre et al., 
2010(M. 
Cloitre et al., 
2010) 
Cloitre et al., 
2012(Marylè
ne Cloitre, 
Petkova, 
Wang, & Lu, 
2012) 
CBT-M (33) 
CBT-M (38) 
CBT-M (33) 
16 weeks (3 mths, 
6 mths) 
Female 
Mixed childhood 
abuse 
63.1 to 64.5 36 
 
100 64 
 
Medium 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments (cont) 
Study Arm (N) Duration (Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age 
(y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
Cook et al., 
2010(Cook 
et al., 2010)
IRT (61) 
PsychEd (63) 
6 weeks (1 mth, 3 mths,6 mths) Male  
Combat 
79.5 to 81.3 59 0 58 Medium 
Cottraux et 
al., 
2008(Cottra
ux et al., 
2008) 
CBT-M (31) 
SC (29) 
16 weeks (1 yr, 2 yrs) Male & Female 
Mixed 
PCLS 
60.8 
39 
 
70 NR Medium 
Dunne et 
al., 
2012(Dunn
e, Kenardy, 
& Sterling, 
2012)  
CBT-M (13) 
WL (13) 
 
 
 
10 weeks (6 mths) Male & Female 
MVA Whiplash 
PDS 
21.39 to 23.31 
33 50 NR Medium 
Ehlers et 
al., 
2003(Ehlers 
et al., 2003)
CT (28) 
SHB (28) 
RA (29) 
Mean 9 weeks, 0 to 3 booster 
sessions, (3 mths, 6 mths, 9 
mths) 
Male & Female 
MVA 
PDS 
(frequency) 
30.0 
PDS (distress) 
30.8  
39 72 97 Medium 
Ehlers et 
al., 
2005(Ehlers
, Clark, 
Hackmann, 
McManus, 
& Fennell, 
2005) 
CBT-M (14) 
WL (14) 
4 to12 weeks plus up to 3 
monthly boosters (3 mths,6 
mths) 
Male & Female 
Mixed 
CAPS-
frequency 
31.6 to 42.0 
CAPS-intensity
29.0 to 36.5 
37 54 4 
 
Medium 
Ehlers et 
al., 
2014(Ehlers 
et al., 2014) 
CT – Intensive (30) 
CT – Weekly (31) 
SC (30) 
WL (30) 
7 day to 3 months (7 mths, 10 
mths) 
Male & Female 
Mixed 
69.95 to 78.72 39 59 30 Medium 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments (cont) 
Study Arm (N) Duration (Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age 
(y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
Fecteau et 
al., 
1999(Fecte
au & Nicki, 
1999) 
CBT-M (22) 
WL (21) 
4 weeks (6 mths) Male & Female  
MVA 
70.9 to 77.3 41 70 NR Medium 
Foa et al., 
1999(Foa et 
al., 1999) 
Zoellner et 
al., 
1999(Zoelln
er, Feeny, 
Fitzgibbons, 
& Foa, 
1999) 
SIT (26) 
PE (25) 
CBT-M (PE+SIT) (30) 
WL (15) 
9 weeks (3 mths, 6 mths, 9 
mths) 
Female 
Assault 
PSS-I 
29.4 to 32.9 
35 100 36 Medium 
Foa et al., 
2005(Foa et 
al., 2005) 
Total 190   
PE (NR) 
CBT-M (PE+CR) (NR) 
WL (NR) 
9 to 12 weeks Female 
Assault 
PSS-I 
31.1 to 34.0 
 
31 100 51 Medium 
Foa et al., 
2013(Foa et 
al., 2013)  
PE + Naltrexone (40) 
PE + Placebo (40) 
SC + Naltrexone (42) 
SC + Placebo (43) 
12 weeks + 6 bi-weekly (3mths, 
6 mths) 
Male & Female  
Comorbid SUD 
Mixed 
PSS-I 
27.1 to 30.3 
43 35 70 Medium 
Forbes et 
al., 
2012(Forbe
s et al., 
2012) 
CPT (30) 
TAU (29) 
12 weeks (3mths) Male & Female 
Combat/Military 
Related 
65.8 to 75.5 53 3 0 Medium 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments (cont) 
Study Arm (N) Duration (Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age 
(y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
Ford et al., 
2011(Ford, 
Steinberg, 
& Zhang, 
2011) 
 
Trauma Affect 
Regulation (48) 
PCT (53) 
WL (45) 
12 sessionsb (3mths, 6mths) Female  
Victimization or 
incarceration 
61.9 to 68.7 31 100 59 Medium 
Gamito et 
al., 
2010(Gamit
o et al., 
2010) 
VR (5) 
IE (2) 
WL (3) 
12 sessionsb Male 
Combat 
NR 64 0 NR Medium 
Gersons et 
al., 
2000(Gerso
ns, Carlier, 
Lamberts, & 
van der 
Kolk, 2000)
BEP (22) 
WL (20) 
16 weeks (3 mths) Male & Female 
Police officers; 
Trauma type NR 
NR  37 12 NR Medium 
Hien et al., 
2004(D. A. 
Hien, 
Cohen, 
Miele, Litt, 
& Capstick, 
2004) 
Total 107 
SS (unclear) 
RPC (unclear) 
UC (unclear) 
12 weeks Female  
Mixed w/Substance 
Abuse Disorders 
70.4 to 73.9 37 100 63 Medium 
Hien et al., 
2009(D. A. 
Hien et al., 
2009) 
Hien et al., 
2012(Denis
e A. Hien et 
al., 2012) 
SS (176) 
PsychEdc (177) 
6 weeks Female 
Mixed 
61.6 to 64.2 39 100 54 Medium 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments (cont) 
Study Arm (N) Duration (Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age 
(y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
Hinton et 
al., 
2005(Hinton 
et al., 2005)
CBT-M (20) 
WL (20) 
12 weeks Male & Female 
Cambodian refugees
74.9 to 75.9 52 60 100 Medium 
Hinton et 
al., 
2009(Hinton
, Hofmann, 
Pollack, & 
Otto, 2009) 
CBT-M (12) 
CBT-M (12) 
12 weeks Male & Female 
Cambodian refugees
Witnessed genocide 
75.4 to 77.3 50 
 
60 100 Medium 
Hinton et 
al., 
2011(Hinton
, Hofmann, 
Rivera, 
Otto, & 
Pollack, 
2011) 
CBT-M (12) 
Relax (12) 
14 weeks (12 weeks) Female 
Trauma NR 
PCL 
69.8 to 71.1 
50 
 
100 100 Medium 
Hogberg et 
al., 
2007(Hogb
erg et al., 
2007) 
EMDR (13) 
WL (11) 
2 mths Swedish public 
transportation 
employees 
IES  
39 
43 21 NR Medium 
Hollifield et 
al., 
2007(Hollifi
eld, 
Sinclair-
Lian, 
Warner, & 
Hammersch
lag, 2007) 
Acupuncture (29) 
CBT-M(28) 
WL (27) 
12 weeks (3 mths) Male &Female 
Mixed 
PSS-SR  
30.8 to 32.5       
42 48 24 Medium 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments (cont) 
Study Arm (N) Duration (Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age 
(y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
Johnson et 
al., 
2011(Johns
on, Zlotnick, 
& Perez, 
2011) 
CBT-M (35) 
UC (35) 
8 months (1 wk, 3 mths, 6 
mths) 
Female 
Interpersonal 
violence 
53.3 to 62.7 33 100 57  Medium 
Krakow et 
al., 
2001(Krako
w et al., 
2001) 
IRT (88) 
WL (80) 
3 sessions (2 a wk apart,1 
session 3 wks later) b (3 mth, 6 
mth) 
Female Sexual 
abuse, assault 
79.6 to 81.9 
 
38d 100 21 Medium 
Kruse et al., 
2009(Kruse, 
Joksimovic, 
Cavka, 
Woller, & 
Schmitz, 
2009) 
CBT-M (35) 
UC (35) 
3 mths wkly; then once every 2 
weeks for total of 25 hrs (12 
mths) 
Male & Female 
Refugees 
NR 45 
 
67 NR Medium 
Kubany et 
al., 
2003(Kuban
y, Hill, & 
Owens, 
2003) 
CBT-M (19) 
WL (18) 
8 to 11 sessionsb (3 mths) Female 
Interpersonal 
violence 
80.1 to 80.2 35 100 51 Medium 
Kubany et 
al., 
2004(Kuban
y et al., 
2004) 
CBT-M (63) 
WL (62) 
4 to 5.5 weeks (3mths, 6mths) Female 
Interpersonal 
violence 
74.1 to 74.4 42 100 47 Medium 
Liedl et al., 
2011(Liedl 
et al., 2011)
CBT-M (12) 
CBT-M (12) 
WL (12) 
10 sessionsb (mean of 4.8 
months) (3 mths) 
Male & Female 
Refugees w/chronic 
pain 
PDS 
25.6 to 31.2 
42 43 NR Medium 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments (cont) 
Study Arm (N) Duration (Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age 
(y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
Lindauer et 
al., 
2005(Linda
uer et al., 
2005) 
BEP (12) 
WL (12) 
16 weeks Male & Female 
Mixed 
NR 39 54 NR Medium 
Litz et al., 
2007(Litz, 
Engel, 
Bryant, & 
Papa, 2007)
CBT-M (24) 
SC (21) 
8 weeks (3 mths, 6 mths) Male & Female 
Combat 
PSS-I 
26.7 to 29.2 
39 22 30 
 
Medium 
Marks et al., 
1998(Marks
, Lovell, 
Noshirvani, 
Livanou, & 
Thrasher, 
1998) 
Lovell et al., 
2001(Lovell, 
Marks, 
Noshirvani, 
Thrasher, & 
Livanou, 
2001) 
PE (23) 
CR (13) 
CR+PE (24) 
Relax (21) 
10 sessions (mean of 16 
weeks), (1 mth, 3 mths, 6 mths)
Male & female 
Mixed 
CAPS Severity
2.6 to 3.2 
38 36 NR Medium 
 
McDonagh 
et al., 
2005(McDo
nagh et al., 
2005) 
CBT-M (29) 
PCT (22) 
WL (23) 
14 weeks (3 mths, 6 mths) Female 
Childhood sexual 
abuse 
67.7 to 72.0 41 100 7 Medium 
Mills et al.,  
2012(Mills 
et al., 2012) 
COPE + UC (55) 
UC (48) 
 
 
13 weeks (9 mths) Male & Female 
Comorbid SUD 
Mixed 
89 to 91 34 64 15 Medium 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments (cont) 
Study Arm (N) Duration (Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age 
(y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
Monson et 
al., 
2006(Mons
on et al., 
2006) 
CPT (30) 
WL (30) 
10 weeks (1 mth) Male & Female 
Combat 
76.7 to 
79.1 
54 10 4 Medium 
Mueser et 
al., 
2008(Mues
er et al., 
2008) 
CBT-M (54) 
UC (54) 
12 to 16 sessionsb Male & Female 
Mixed 
74.5 to 76.2 44  
 
79 16 
 
Medium 
Nacasch et 
al., 
2011(Nacas
ch et al., 
2011) 
PE (15) 
TAU (15) 
9 to 15 weeks (12 mths) Male & Female  
Combat or Terror 
PSS-I 
36.8 to 37.1 
34 NR 100 Medium 
Neuner et 
al., 
2004(Neun
er, Schauer, 
Klaschik, 
Karunakara, 
& Elbert, 
2004) 
NET (17) 
Trauma Couns (14) 
PsychEd (12) 
3 to 4 weeks (4 mths,12 mths) Male & Female 
Sudanese refugees 
PDS 
19.5 to 25.2  
33 61 100 Medium 
Neuner et 
al., 
2008(Neun
er et al., 
2008) 
NET (111) 
Trauma Couns (111) 
MG (No Intervention) 
(55) 
3 weeks (6 mths) Male & Female 
Rwandan and 
Somalian refugees 
PDS 
21.3 to 26.7 
 
35 51 100 Medium 
Neuner et 
al., 
2010(Neun
er et al., 
2010) 
NET (16) 
TAU (16) 
Weekly or bi-weekly sessions 
(median 9) e 
Male & Female 
Asylum Seekers 
PDS 
36.9 to 38.9 
31 31 NR Medium 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments (cont) 
Study Arm (N) Duration (Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age 
(y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
Nijdam et 
al., 
2012(Nijda
m, Gersons, 
Reitsma, de 
Jongh, & 
Olff, 2012) 
BEP (70) 
EMDR (70) 
17 weeks Male & Female 
Mixed 
IES-R 
72.8 to 79.9 
38 56 100 Medium 
Resick et 
al., 
2002(Resic
k, Nishith, 
Weaver, 
Astin, & 
Feuer, 
2002) 
Resick, et 
al., 
2003(Resic
k, Nishith, & 
Griffin, 
2003) 
Resick et 
al., 
2012(Resic
k, Williams, 
Suvak, 
Monson, & 
Gradus, 
2012) 
CPT (62) 
PE (62) 
MA (47) 
6 weeks (3 mths, 9 mths, 5 to 
10 years) 
Female 
Adult sexual assault 
CAPS-SX 
69.9 to 76.6 
32 100 29 Medium 
Rothbaum 
et al., 
1997(Rothb
aum, 1997)
EMDR (11) 
WL (10) 
4 weeks (3 mths) Female 
Sexual assault  
PSS-I 
33.3 to 39.0 
35 100 NR Medium 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments (cont) 
Study Arm (N) Duration (Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age 
(y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
Rothbaum 
et al., 
2005(Rothb
aum, Astin, 
& 
Marsteller, 
2005) 
PE (24) 
EMDR (26) 
WL (24) 
4.5 weeks (6 mths) Female 
Sexual assault 
Data Reported 
in Graphs only 
 
34 100 32 Medium 
Rothbaum 
et al., 
2006(Rothb
aum et al., 
2006) 
Sertraline 25 to 200+PE 
(34) 
Sertraline 25 to 200 (31) 
6 weeks Male & Female 
Mixed 
SIP 
15.3 
39 65 20 Medium 
Sannibale 
et al. 
2013(Sanni
bale et al., 
2013)  
IT (33) 
Alcohol SC (29) 
 
12 weeks (9 mths) Male & Female 
Australian  
Mixed 
68.03 41 53 NR Medium 
Schneier et 
al., 
2012(Schne
ier et al., 
2012) 
PE+paroxetine 12.5 to 
50 (19) 
PE+placebo (18) 
10 to 22 weeks Male & Female 
World Trade Center 
Attack 
65.4 to 72.6 50 54 32 Medium 
Schnurr et 
al., 
2003(Schnu
rr et al., 
2003) 
Group exp (180) 
PCT (180) 
30 weeks, 5 subsequent 
monthly boosters (12 months 
total) 
Male 
Combat 
80.4 to 82.1 51 
 
0 34 
 
Low 
Schnurr et 
al., 
2007(Schnu
rr et al., 
2007) 
PE (141) 
PCT (143) 
10 weeks (3 and 6 months) Female 
Mixed 
77.6 to 77.9  45  100 46 Medium 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments (cont) 
Study Arm (N) Duration (Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age 
(y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
Schnyder, 
2011(Schny
der, Muller, 
Maercker, & 
Wittmann, 
2011) 
BEP (16) 
MA (14) 
16 weeks (6 mths) f Male & Female 
Mixed 
73.4 to 78.6  40 47 NR Medium 
Spence et 
al., 
2011(Spenc
e et al., 
2011) 
CBT-M (23) 
WL (21) 
8 weeks (3 mths) Male & Female 
Mixed 
PCL-C 
57.0 to 60.8  
43 
 
81 NR Medium 
Tarrier et 
al., 
1999(Tarrie
r et al., 
1999; 
Tarrier, 
Sommerfiel
d, Pilgrim, & 
Humphreys, 
1999) 
IE (35) 
CT (37) 
16 sessions (112 days) (6 and 
12 mths) 
Male & Female 
Mixed 
71.1 to 77.6 39 42 NR Medium 
Taylor et 
al., 
2003(Taylor 
et al., 2003)
Relax (19) 
PE (22) 
EMDR (19) 
8 weeks (1 mth,3 mths) Male & Female 
Mixed  
NR 37 75 23 Medium 
van der 
Kolk et al., 
2007(van 
der Kolk et 
al., 2007) 
EMDR (29) 
Fluoxetine (30) 
Placebo (29) 
8 weeks (6 mths) Male & Female  
Mixed 
71.2 36 83 33 Medium 
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TABLE S3.  Characteristics of Included Trials Evaluating Psychological Treatments (cont) 
Study Arm (N) Duration (Followup) 
Population Trauma 
Type 
Baseline 
PTSD 
Severitya 
Mean 
Age 
(y) 
Mean 
% F 
Mean % 
Non-
white 
Risk of 
Bias 
van 
Emmerik et 
al., 
2008(van 
Emmerik, 
Kamphuis, 
& 
Emmelkam
p, 2008) 
CBT-M (41) 
Writing (44) 
WL (40) 
5 sessionsb (Mean 119.5 days), 
91-973 days 
Male & Female 
Mixed 
IES 
46.4 to 49.1 
40 67 NR Medium 
Zlotnick et 
al., 
2009(Zlotni
ck, 
Johnson, & 
Najavits, 
2009) 
SS (27) 
RPC (22) 
6 to 8 weeks (3 mths, 6 mths) Female 
Mixed 
64.4 to 69.4 35 100 53 Medium 
CAPS-SX= Clinician Administered PTSD Scale for DSM-IV: One-Week Symptom Status Version; CBT Cope= cognitive behavioral therapy-coping skills; CBT-M= cognitive behavioral 
therapy mixed ; CPT= cognitive processing therapy; CT= cognitive therapy; CR= cognitive restructuring; DTS= Davidson Trauma Scale; EMDR= eye movement desensitization and 
reprocessing; F= Female; IE= imaginal exposure; IES= Impact of Events Scale; In vivo exp= in vivo exposure;  MA= minimal attention (a type of waitlist group); M-PTSD=Mississippi 
Scale for Combat-related PTSD; MVA= motor vehicle accident; N= total number randomized/assigned to intervention and control groups; NR= not reported; PCL-C= Posttraumatic 
stress disorder checklist-civilian Version; PCLS= Post-Traumatic Stress Disorder Checklist Scale; PDS= Posttraumatic Stress Diagnostic Scale; PE= prolonged exposure; PSS-I= 
PTSD Symptom Scale—Interview; PE= prolonged exposure; PSS-I= PTSD Symptom Scale—Interview; PSS-SR= Posttraumatic Symptom Scale-Self Report;  PsychEd= Psychosocial 
education; PTSD=Posttraumatic Stress Disorder; RA= Repeated Assessments (a type of waitlist group); Relax= relaxation; RPC= relapse prevention condition; SHB=Self-help booklet 
based on principles of CBT; SIT= stress inoculation training; SC= supportive control; SS= seeking safety;  TAU= treat as usual; Trauma Couns=  Trauma Counseling; UC= usual care; 
WL= waitlist; Writing=structured writing therapy; y=years. 
When mean data for baseline PTSD severity was not reported for the total sample but was presented for each study arm, we provide the range across arms. 
aData reported are mean CAPS total or range of mean CAPS total scores across groups unless otherwise specified. 
bNumber of treatment sessions reported when duration of treatment not specified. 
cPsycho Ed in this study is “Women’s Health Education” (WHE). 
d Mean age based on the completers in sample. 
eTreatment was terminated at the discretion of the therapist; range of 5-17 sessions provided. 
fOnly the BEP group had a follow-up assessment; the control group did not. 
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